A new deal between major pharmaceutical companies and the Trump administration will see the price of GLP-1 weight‑loss drugs lowered significantly under Medicare and Medicaid.
The deal was struck between President Donald Trump, Danish pharma giant Novo Nordisk and American company Eli Lilly.
It will see price cuts for the drugs, such as Ozempic and Wegovy, of hundreds of dollars for those on Medicare and Medicaid, as well as regular cash customers.
Currently, Medicare does not usually cover the drugs for obesity, while Medicaid varies on a state-by-state basis.
The savings will reportedly range from $149 to $350 a month on average, with current costs landing anywhere from $500 to $1,000 per month.
"It's going to equalise the world," Trump told reporters from the Oval Office.
"They’ve often cost consumers more than $1,000 per month, some a lot more than that…That ends starting today.”
